肾素拮抗剂进展与临床应用评价  

Progress and Clinical Evaluation on Renin Antagonist

作　　者：张石革[1] 苗健伟[1] 

机构地区：[1]北京大学第四临床医学院,北京积水潭医院,北京市100035

出　　处：《中国医院用药评价与分析》2009年第3期167-169,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:肾素-血管紧张素-醛固酮系统是人体内重要的血压调节机制之一,对后两个环节的抑制而促成了血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体阻断剂、醛固酮拮抗剂的生产和应用,成为对抗高血压临床应用的一线药,而肾素拮抗剂的问世则为抗高血压药团队中增添了一朵奇葩。方法:通过对国内外近期文献的复习,对肾素拮抗剂阿利克仑进行评价。结果及结论:在大量的临床研究中,阿利克仑显示了良好效果和安全性,在控制血压的治疗上标志着一个新里程的开始。OBJECTIVE： Renin angiotensin aldosterone system is one the most important regulatory mechanisms in human body, its inhibitory action on the last two links contributed to the production and applications of angiotensin converting enzyme inhibitor （ACEI）, AGT Ⅱ receptor blockers and aldosterone antagonists, which have become the first line antihypertensive drugs in the clinic; whereas the presence of renin antagonist is an exotic flower added to aldosterone antagonists. METHODS： The Renin Antagonist Aliskeren reported in recent literature both at home and abroad was reviewed. RESULTS ＆ CONCLUSION： Considerable clinical studies have proved that aliskeren has remarkable efficacy and good safety, and its presence marks a new start in the management of hypertension.

关 键 词：肾素拮抗剂 阿利克仑 进展 临床评价 

分 类 号：R972.4[医药卫生—药品]